Select a Region North America

EVERSANA™ COMPLETE Commercialization

Drive Value, Minimize Risk  and Increase Speed to Market

Next Generation Commercialization

Companies spend >$200MM over three years leading up to launch, and 66% of drugs still don’t meet launch expectations. This looming risk, echoed by general industry pressures, leaves developers and investors alike looking for more advanced commercialization options that effectively maximize their pipelines.

EVERSANA™ COMPLETE Commercialization, an award-winning model that is disrupting the pharma industry, offers an alternative to selling, out-licensing or launching internally.

Whether you are an emerging pharma or an established brand, this innovative model can help you achieve flexible, agile product launches that meet client and patient needs.

For small and emerging pharma, this model:
  • Affords investors full access to a complete end-to-end commercialization model.
  • Delivers more value than traditional licensing or launching on your own.
  • Activates a complete, ready-to-deploy, high-performance commercialization and distribution engine.
  • Accelerates your product from early development to marketing, effectively impacting patient outcomes and beyond.
For established brands, this model:
  • Eliminates capability and capacity restraints to increase the throughput of in-licensed assets.
  • Serves as a catalyst for biopharma companies to address the management of their established brand portfolios.

Case Studies: Real-World Impact

Leveraging our data and analytics platform, our team works together to produce the best outcomes for our partners and their patients.

  • AGILITY

    AGILITY

    Our team is trained to proactively monitor market conditions, the commercial readiness of the program and course-correct in an agile manner.

    View Case Study
  • SPEED

    SPEED

    Our integrated systems and culture allow us to mobilize the execution team quickly and communicate efficiently to create a positive customer experience.

    View Case Study
  • Risk Management

    Risk Management

    Our proven, ready-to-deploy commercialization model minimizes operational and financial risks for our partners.

    View Case Study
See how pharma companies are using this new model effectively by downloading the article Reinventing Launch: The Gold Standard of Drug Commercialization by Greg Skalicky, Chief Revenue Officer.


A Deeper Dive into Our Model 

Imagine not having to risk building an expensive infrastructure – because we have built a foundation you can customize for your product needs. Activate a complete, ready-to-deploy, high-performance commercialization and distribution engine today!

True Financial Benefit

A recent study examined 10 real-world pharma launches and compared them to companies that embraced this new, innovative, scalable commercialization model. The study concluded that those who launched in the traditional model overspent by 23%, without any upside on launch success. Download the white paper to see an in-depth analysis of all launches and costs.

Predictable Commercial Success

Complete, full-scale, customizable infrastructure amplified by top industry launch leaders

Engineered to:

  • optimize the launch of precommercial assets
  • capture full revenue potential through maturity

Revolutionary, nontraditional financial deal structures provide flexibility of terms and options

Built to:

  • provide an alternative to traditional and more common strategies, such as selling it, out-licensing or going at it alone
  • reduce up-front cash investments necessary to launch
  • maximize revenue potential and minimize financial risk

Valuable assets demand integrated, predictive and actionable data to maximize growth potential

Empowered to:

  • maximize the ROI of data and analytic investments
  • enhance decision-making
  • create a seamless patient journey and positively impact outcomes

When A Curveball Threatens Your Product’s Launch

In this 3-minute video, Mike DeLaroche shares a new commercializing model that mitigates risk and combats curveballs that manufacturers cannot predict when launching products.

Recent Commercialization Partnerships

Australian AI Company Artrya Announces Major UK Commercialisation Partnership With EVERSANA

AI medical technology company Artrya Limited is announcing its partnership with leading global commercial services provider EVERSANA Life Sciences LLC (“EVERSANA”) as its launch and commercialisation partner to access the UK market. Read the full story.

Q BioMed Bolsters Commercialization of Strontium89 with EVERSANA Partnership

Q BioMed Inc. a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, today announced it has engaged EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to immediately support the commercialization of Strontium89, an FDA-approved cancer bone palliation radiotherapy. Read the full story. 

MINDPAX and EVERSANA announce U.S. commercialization partnership to launch revolutionary digital therapeutic solution for bipolar disorders

The leadership team at MINDPAX Inc., the leading digital therapeutic company focused on bipolar disorders, today announces its partnership with EVERSANA™ to launch and commercialize its therapeutics in the United States. MINDPAX combines remote clinical assessment and targeted digital therapy to improve patients’ clinical conditions. Read the full story.

Shorla Pharma Announces Partnership with EVERSANA to Support the Launch and Commercialization of T-cell Leukemia Treatment

Shorla Pharma (‘Shorla’), a specialty pharmaceutical company, and EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, today announced a partnership to support the launch and commercialization of Shorla’s oncology portfolio. Read the full story.

GENinCode announces major US commercialisation partnership with EVERSANA

GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, is partnering with EVERSANA  to be the launch and commercialisation partner to access the United States market for the GENinCode portfolio of polygenic cardiovascular disease (“CVD”) products focused on genetic risk. Read the full story.

Resverlogix and EVERSANA Announce Partnership to Support the Launch of Apabetalone for COVID-19 in the United States and Canada

Resverlogix Corp. and EVERSANA announced a partnership to support planned commercialization of apabetalone in the United States, Canada (where authorization has been granted to conduct clinical studies of apabetalone for COVID-19) and/or potentially expanding to additional global markets, as Emergency Use Authorization and/or a New Drug Application or equivalent is issued or approved. Read the full story.

联系我们

Schedule a meeting today!

Contact us to discuss how your asset can immediately benefit from EVERSANA™ COMPLETE Commercialization.

Contact Form

  • 这个字段是用于验证目的,应该保持不变。

Related Articles

Succeed When Others Fail: Avoiding 20% in Investment Waste During Launch

It’s a long-standing perception that pharma overspends during launch, but we did not have the data or methodology to understand or validate this notion. Until now.  New Research by the Numbers 10: Recent analysis across 10 traditional launches where the manufacturer opted to commercially launch a new drug  $345M: The total cost for a manufacturer […]

CHALLENGING TRADITION: The argument for integrated commercialization to improve operational agility

Today’s economics simply do not support building commercial capabilities from scratch, only to dismantle that infrastructure until the next need arrives. Manufacturers will spend approximately $200 million of commercialization costs over three years leading up to the launch of their product, yet 66% of drugs do not meet launch expectations.    In an era of specialty and […]

Case Study: Launching a New Therapy for HER2-Positive Metastatic Breast Cancer

When MacroGenics partnered with EVERSANA, they had less than five months to launch their first product in the midst of the global pandemic. To meet their timeline and streamlined launch, MacroGenics needed a commercialization partner with an end-to-end platform that would allow them to build their capabilities expeditiously and strategically.

A SpaceX Philosophy to Launching in Pharma

In thinking about the economics around the launch of pharmaceutical products, it is useful to compare the situation to another area that has seen its economics evolve in recent years: space travel. For decades, the only reusable space vehicle was NASA’s space shuttle. When the space shuttle was in operation, it could launch a payload […]

Reinventing Launch: The Gold Standard Of Drug Commercialization

In a world that is rapidly changing, we must evolve beyond traditional strategies to create true impact for patients. EVERSANA’s complete end-to-end commercialization model enables manufacturers to bring their drug to market at a fraction of the cost of “going it alone” or partnering with another pharmaceutical company.